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Abstract
Background: De novo tumors (DNT) after liver transplantation (LT) represent a growing concern.
Patients and Methods: We analyzed the incidence of DNT, type, time of onset, risk factors and mortality (as of 2010) in 494
adult patients transplanted in the last 26 years (1983–2009).
Results: DNT occurred in 41 (8.3%) of the patients. The Standardized Incidence Ratio (SIR) compared with the Italian
population was 1.8. There was a higher incidence in males (SIR 2.0), an expected extremely high rate of Kaposi’s sarcoma
(SIR 127.95) and unexpected higher rates of tumors of the bladder in males (SIR 3.3). The incidence of DNT was higher within
the first two years of LT (SIR 2.7) for Kaposi’s sarcoma (SIR 393.3) and after 10 years (SIR 1.7) for bladder tumors (SIR 10.6).
Multivariate analysis identified alcoholic cirrhosis (HR= 3.0, 95% CI = 1.2–7.8) and sclerosing cholangitis (HR = 3.5, 95%
CI = 1.1–11.3) in the recipient as main risk factors for the occurrence of DNT.
Conclusions: Surveillance protocols for DNT must be specifically oriented to patients transplanted for alcoholic cirrhosis and
sclerosing cholangitis. They should focus on early detection of Kaposi’s sarcomas, and more remarkably, on late
development bladder tumors in men after LT.
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Introduction
Liver transplantation (LT) is presently the gold standard therapy
for patients with end-stage liver disease. In recent years, the results
of this procedure have shown a significant and steady improve-
ment in long term survival [1]. Due to these improving results,
early and late problems still occur after liver transplantation [1].
Among late complications, recurrences of primary diseases may be
predictable. De Novo Tumors (DNT) can arise at different times
[2], may be more unpredictable and therefore need specific
attention. Their rate and time of onset as well as pre-disposing
etiological factors should be identified to help screening and
treatment. Published data on DNT arising after liver transplan-
tation indicate a cumulative incidence of 5–6% at 5 years, 13–20%
at 10 and 16% at 20 years [3,4].
The main aim of this study was to compare the rates of different
DNTs among patients who have had a liver transplant with those
of the general population and to evaluate the DNT risk based on
time from transplantation.
Materials and Methods
a) Patients
The Ethics Committee of our institution –Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico of Milan - was notified
of this study. According to Italian law (Gazzetta Ufficiale, serie
generale, n.76, p. 67–74) no specific approval is needed for
retrospective studies.
Informed consent was obtained as usual for medical, surgical,
radiological treatments, not specifically for this retrospective study.
Patients gave written consent for every procedure performed in the
hospital including treatment of data for medical purposes.
Data from 571 adult patients with 644 liver grafts spanning a
period from 1983 to 2009 were analysed. The detection of some
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tumors occurred as early as the second month after LT and thus
we excluded 57 patients (with 67 LTs) with a post-operative
follow-up time #30 days.
Patients transplanted for primary hepatic tumors (i.e. hepato-
mas- HCC) were included, assuming that these tumors did not
influence the occurrence of DNTs.
Cyclosporine was the main immunosuppressive drug from 1983
through march 1993. Thereafter it was often replaced by
Tacrolimus except for HCV patients. OKT3 was sometimes
used. The policy of our Center was to treat HCV patients with
Cyclosporine.
No specific protocol for detecting de novo tumors was
employed. In the post-operative period patients underwent
physical, radiological (in the form of an abdominal ultrasound)
and biochemical assessment. In suspected cases of DNT measure-
ment of tumor markers (alpha-1-fetoprotein, Ca 19–9, Carci-
noembryonic antigen) were included as part of the biochemical
investigation. All data was entered into a retrospective database
specifically for this study. Cancer incidence and mortality follow-
up was performed by collecting clinical information during
periodic pre-scheduled visits from patients/relatives or by periodic
active phone/fax contact.
The follow-up ended on April 30, 2010. Twenty patients were
lost to follow-up bringing the final cohort of patients included in
the study to 557 grafts in 494 adult patients: 437 patients were
transplanted once, 51 twice, and 6 three times.
New primary cancer diagnoses were coded according to the
International Classification of Diseases and Related Health
Problems, 10th revision (ICD-10). Non-melanoma skin cancers
were excluded from analysis in the study. The recurrence of HCC
was not considered an event in our study. For patients residing in
Milan, completeness of cancer identification was checked by
record-linkage with official hospital admissions databases in the
period 2000–2008 and with the Milan cancer registry.
b) Statistical Analysis
The overall and tumor-specific cancer incidence in the cohort of
transplanted patients was compared with the expected incidence
according to national cancer incidence rates (provided by the
Italian Association of Cancer Registries, AIRTum, http://www.
registri-tumori.it/cms/) specific for gender, calendar period, and
age. Person-years at risk for cancer incidence were computed from
30 days after the date of transplant to the date of cancer diagnosis,
date of death, date of last follow-up visit or to the date of
termination of the study (April, 30, 2010), whichever came first.
For each cancer site, we calculated Standardized Incidence Ratios
(SIR) as the ratio of observed (Obs) to expected (Exp) number of
cancer cases; 95% CI of SIRs were calculated using the exact
method based on the Poisson distribution [5]. SIR patterns by
gender and time since LT were evaluated.
The cumulative DNT risk was analyzed using the Kaplan-
Meier estimator [6]. We estimated the association between DNT
risk and selected donor, transplant, and recipient characteristics by
calculating Hazard Ratios (HR) and their 95% confidence
intervals (95% CI) with univariate Cox proportional hazard
models [6]. The covariates of the priori interests and those
emerging from univariate analyses with statistical significance were
then included in a multiple regression Cox model to calculate
adjusted HRs. Several demographic, clinical and biochemical data
related to donor, transplant and recipients were collected and
analysed.
Mortality of DNT patients was compared with that of the not
DNT patients using Kaplan-Meier estimator and Cox regression.
Person-years from 30 days since LT until DNT diagnosis were
considered as cancer-free person-years [7].
Finally, we compared all mortality causes in transplanted
patients with those in the general Italian population by calculating
Standardized Mortality Ratios (SMR) using mortality rates specific
for calendar period (5 year categories), gender, and age (5 year
classes). Statistical analyses were performed using Stata 11
(StataCorp LP, Texas, USA) [8].
Results
The average follow-up time in the 494 pts was 7.2 years
(standard deviation 5.6 years), (range from 33 days to 22 years).
Overall, the person-years at risk from LT to de-novo occurrence
or censoring were 3,761 Years.
Recipient characteristics are reported in Table 1.
Incidence of de Novo Tumors
In 494 liver transplant recipients, 50 DNTs (10.1%) were found,
including 9 (1.8%) non-melanoma skin cancers(Table 2). Exclud-
ing non-melanoma skin cancers, there were 41 (8.3%) patients
with DNTs (31 men and 10 women) with average age at time at
diagnosis of 55 years (standard deviation 9). When compared with
the general Italian population, cancer incidence was higher (SIR
2.00) in males and slightly increased (SIR 1.31) in females. Both
genders had extremely elevated SIRs for Kaposi’s sarcoma (7 cases
overall against only 0.05 expected- per100,000). Male gender
showed elevated SIRs for several sites, including upper aero-
digestive, breast, bladder and hematologic neoplasms (notably
lymphomas). In females, elevated SIRs (based on only one case) for
upper aerodigestive, stomach,uterus and hematologic neoplasms,
and (2 cases) for lung cancer.(SIR 5.3).
The highest incidence of DNT (SIR 2.7) was found within the
first two years of LT (Table 3). Five of the 11 early DNTs were KS
(2 of them within 2 months of LT) with an extremely elevated
SIR(393.3). Among the six remaining cancers occurring within 2
years of LT, we observed one case of stomach, lung, CNS, and
NHL each, with SIRs ranging from 1.9 to 12.3 and two colon
cancers with a SIR of 6.1. 2–9 years after LT, there was a six-fold
excess of upper aerodigestive (laryngo-pharyngeal cancers) can-
cers, KS, and prostate cancer. Ten years after LT there was a clear
excess of bladder cancers with five cases (2 between 10 and 15
years and 3 after 15 years from LT) (SIR 10.6), and of cervix (SIR
22.6) and hematologic cancers (SIR 4.3), but based on a few cases.
There was also a periodic shift in the occurrence of a
predominant malignancy. From 1986–1991 there was a higher
rate of colon cancer (SIR 57.8), from 1992–1996 of lung (SIR
6.22) cancer and lymphomas (SIR 13.6) and from 2006 a higher
rate of Kaposi’s sarcomas (SIR 270.7) and bladder tumors (SIR
6.69).
Specific Aspects: Bladder Cancers
Among five patients with urothelial (transitional cell) bladder
cancers, two tumors were discovered after the onset of gross
hematuria whereas the others during routine abdominal
ultrasound exams. Three patients had early stage tumors,
whereas two had T2 and T3N2 tumors, respectively. Two
patients underwent a Transurethral Resection of a Bladder
Tumor (TURBT), and two a radical cystectomy with extended
pelvic lymph node dissection and ileal conduit urinary diversion.
One patient underwent a TURBT for a T2 cancer, but then
was scheduled for major surgery. Unfortunately he died before
the surgical treatment.
Bladder Tumors after Liver Transplantation
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Risk Factors
The cumulative risk (Kaplan-Meier failure function) of DNT
after LT was 8.9% (95% CI 6.2–12.7%) at 10 years and 22.8%
(95% CI 15.2–33.3%) at 20 years. In the univariate Cox regression
analyses only male gender, alcoholic cirrhosis, and sclerosing
cholangitis were found to be predictors for development of DNT.
The covariates of priori interests and those emerging from
univariate analyses (age and sex of recipient and indications for
LT) were then included in a multiple Cox model to calculate
adjusted HRs. Alcoholic cirrhosis (HR = 3.03, 95% CI 1.17–7.84,
p = 0.02) and sclerosing cholangitis (HR = 3.51, 95% CI = 1.09–
11.34, p = 0.03) were confirmed as independent risk factors.
Mortality
There were 14 deaths among patients with DNT and 119
among patients without DNT. Survival was significantly different
(Figure 1). The gender- and age-adjusted HR of mortality in DNT
patients was 4.4 (95% CI: 2.4–8.0) compared to patients without
Table 1. Clinical characteristics of 494 adult recipients who underwent primary liver transplantation, 1983–2009.
Demographic and clinical characteristics of Recipients 494 patients
n %
Sex
Male 334 58.3
Female 160 27.9
Age (mean, SD) 46.8, 10.8
median (range) 49.0 (19–66)
Geographic area of birth
Northern Italy 197 43.8
Central Italy 16 3.6
Southern and insular Italy 215 47.8
Out of Italy 22 4.9
Unknown 44
Indication to transplantation
Virus related cirrhosis 201 40.7
Hepatic Tumors (HCC+CCC) 108 21.9
Alcoholic cirrhosis 36 7.5
Sclerosing cholangitis 20 3.8
Primary Biliary cirrhosis 35 7.3
Fulminant/subfulminant hepatic failure 27 5.5
Others 67 13.4
Virus induced disease 314 63.6
HCV (Hepatitis C virus) 181 36.6
HBV (Hepatitis B virus) 151 30.6
Starting immunosuppression
Cyclosporine 281 56.9
Tacrolimus 155 31.4
Not available 58 11.7
Retransplantations 57 11.5
Causes of death N= 131 22.9
Sepsis 30 22.9
Miscellaneous 28 21.4
Non tumor recurrence 20 15.3
Tumor recurrence 15 11.5
De novo tumors 41 10.7
Technical failures 12 9.2
Primary o Delayed non function 5 3.8
Rejection 4 3.1
Perioperative death. after long follow-up 3 2.3
Follow-up time (years), mean, SD 7.2, 5.6
median (range) 5.6 (33 days - 22 years)
doi:10.1371/journal.pone.0065238.t001
Bladder Tumors after Liver Transplantation
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DNT. There were no differences (p = 0.71) in survival between
patients with different kinds of DNT (Upper Aerodigestive, Lung
tumors, Kaposi’s sarcomas and others) (data not shown).
Compared to the general Italian population, there was a
dramatic reduction in mortality over time in transplanted patients
both without (standardized Mortality Ratios –SMR – from 59.7 in
1983–1989 to 2,9 in 2005–2010), and with DNT (SMR from
269.2 in 1983–1989 to 5.2 in 2005–2010) compared to the Italian
Mortality Rates (data not shown).
Discussion
This is the largest and longest single centre Italian collection of
DNT after LT series to date.
DNT represents a complication that has increasingly gained
importance, partly due to improvements of liver transplantation
[9]. The only available international register from the centers of
liver transplantation, the Israel Penn International Transplant
Tumor Registry (IPITTR) [10], contains valuable information on
this subject but provides no data on patient follow-up and risk rate
for DNT occurrence in transplanted patients [11]. Studies
reported in the literature are quite heterogeneous as, there was
neither standardization among the series of patients who presented
with DNT nor between the analytical methods. Other differences
include the number of patients, ranging from 325 to 6846
[2,19,10,11,12,13] and duration of observation time – from 5 to
27 years - in different periods ranging form 80s to 2006
[2,10,11,14,3,15], that could affect the results.
Distinct from most other European studies [16,17,18] with the
exception of the series of Collett and Al. (19), the follow-up of our
patients is quite long, as our first liver transplant was performed in
1983, allowing a broader perspective on this problem.
The incidence of DNT in patients undergoing liver transplan-
tation varies between 3 and 26% [9,12,3] and increases with
duration of follow-up. The cumulative risk of DNT has been
estimated to be 6%,20% and 55% at 5, 10 and 15 years
respectively [20], or 3%, 5%, 13% and 16% at 1,5,10 and 20 years
respectively [3].
In the few studies that have calculated SIRs for DNT the
reported figures ranges from 2.2 to 4.0 [2,19,11,3,15,20].
The incidence of DNT in our cohort of patients was 8.3%. The
SIR compared to the Italian cancer registries was 1.8. Our rates
and SIR were slightly lower compared to other reported Italian
series [2,11]. This difference has no clear explanation. Relative to
patients studied in the Baccarani’s paper [2] our population is
younger and more frequently coming from Southern Italy.
In the published literature males appear to be more affected
than females (ratio 3.29 vs 2.35) [12]. In our series, males
presented an overall higher SIR for DNT than women (2 vs 1.3).
Females had higher SIRs for cancers of the lung and Kaposi’s
Table 2. Observed (Obs) and expected (Exp) cases of de-novo tumors, Standardized Incidence Ratios (SIR), and 95% Confidence
Intervals (95% CI) among 494 adult recipients who underwent primary liver transplantation, 1983–2009, by gender. Reference: pool
of Italian cancer registries.
Males Females Total
Cancer site/type
(ICD-10 code) Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All cancers but skin
(C00–C43, C44–C 97)
31 15.4 2.0 1.4–2.9 10 7.6 1.3 0.6–2.4 41 23.0 1.8 1.2–2.4
Upper aerodigestive
(C00–C14, C30–C33)
3 1.0 2.9 0.6–8.4 1 0.1 8.7 0.2–48.7 4 1.2 3.4 0.9–8.8
Stomach (C16) 0 0.7 0 1 0.2 5.3 0.1–29.8 1 0.9 1.2 0.03–6.5
Colon (C18) 3 1.3 2.2 0.5–6.5 0 0.6 0 3 1.9 1.6 0.3–4.6
Lung (C33–C34) 4 2.5 1.6 0.4–4.2 2 0.4 5.3 0.6–19.0 6 2.8 2.1 0.8–4.6
Kaposi’s sarcoma (C46) 6 0.05 120.0 44.0–261.0 1 0.005 212.7 5.4–1185.3 7 0.05 127.9 51.4–263.5
Breast (C50) 1 0.04 22.6 0.6–126.1 2 3.0 0.7 0.08–2.4 3 3.0 1.0 0.2–2.9
Vulva (C51.9)* 1 – 1 –
Uterus, cervix (C53) 1 0.2 5.7 0.1–31.9 1 0.2 5.7 0.1–31.9
Prostate (C61) 4 2.5 1.6 0.4–4.1 4 2.5 1.6 0.4–4.1
Bladder (C67) 5 1.5 3.3 1.1–7.6 0 0.2 0 5 1.7 2.9 1.0–6.9
Central nervous system
(C69–C72)
1 0.3 3.4 0.1–19.1 0 0.1 0 1 0.4 2.4 0.1–13.5
Hematologic cancers
(C81–C96)
4 1.2 3.3 0.9–8.4 1 0.5 1.9 0.1–10.8 5 1.7 2.9 0.9–6.7
Lymphomas (C81–C85,
C96)
4 0.7 5.9 1.6–15.1 0 0.3 0 4 1.0 4.1 1.1–10.4
Non–Hodgkin’s
lymphoma (C82–C85,
C96)
3 0.6 5.0 1.0–14.7 0 0.3 0 3 0.9 3.5 0.7–10.2
Hodgkin’s disease (C81) 1 0.1 12.5 0.3–69.4 0 0.04 0 1 0.1 8.2 0.2–45.4
Leukemia (C91–C95) 0 0.3 0 1 0.1 8.2 0.2–45.5 1 0.5 2.2 0.1–12.3
Reference: pool of Italian cancer registries.
*Reference rates not available.
doi:10.1371/journal.pone.0065238.t002
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sarcoma whereas men had higher SIRs for cancers of the bladder,
colon, and lymphomas.
The age of onset of cancers has been reported to be similar
between transplanted patients and the general population [10]
according to a recent large study of the Israeli population by Miao.
Aberg et al reported that 80% of DNT after liver transplantation
affects individuals between 45 and 74 years [3]. This view is
supported by Haagsma [4] and Fung [21] who note that there is a
positive correlation between incidence of cancer and age over 40
years. Conversely, it appears that there is a negative correlation
between lymphoproliferative disorders (PTLD) and age.
In our series, the age range associated with a higher frequency
of tumors was 55–59 years. This is consistent with the fact that in
the general population the incidence of cancer increases with age.
However, if we consider the SIR, the greatest increase if compared
to the general population, is between 20 and 24 years - in relation
to Kaposi’s sarcoma - and between 40 and 44 years.
Viral infections appear to contribute to the development of
DNT. In immunocompetent subjects, cervical cancer has been
linked to Human Papilloma Virus infections, and Kaposi’s
sarcoma with Human Herpes Virus 8. Infection with Epstein
Barr Virus is the main risk factor for developing lymphoprolifer-
ative disorders [12,13,18], nasopharyngeal cancer and some types
of leiomyosarcoma. HCV has a controversial role [12].
All studies [2,19,11,13,22,23,24] agree that among primary
hepatic diseases leading to liver transplantation, alcohol seem to be
related to an increased rate of DNT, particularly skin cancers,
cancers of the oral cavity, larynx and esophagus. Smoking has
been recognized by several authors as a general [25,26,27] and
specific risk factor for esophageal [12], skin [28] and lung [29]
cancers. Unfortunately, one limitation of this study is that we were
not able to evaluate smoking as a risk factor for DNT.
Delco` [30] found a significant correlation between primary
sclerosing cholangitis and cancer, and specifically with colorectal
cancer. In our series only one out of three colon cancers occurred
in a patient transplanted because of a primary sclerosing
cholangitis; however primary sclerosing cholangitis and alcoholic
cirrhosis confirmed a strong statistical relationship with the onset
of DNT.
With regard to immunosuppressive drugs, though there are
some confirmations of the association between the use of
cyclosporin and non-melanoma skin cancers [31], in our series a
comparison of the two calcineurin inhibitors with the development
of DNT showed no statistical difference. In addition, the use of
monoclonal antibodies, such as OKT3, also failed to show any
statistical significance.
We also observed an higher rate of lymphomas in the early
years of transplantation (1991–1996), but of kaposi’s sarcoma and
bladder tumors after 2006. No specific correlation with initial
immunosuppressive therapy concerning calcineurin inhibitors was
found even though treatment with cyclosporine was more frequent
in the early years. The influence of other immunosuppressive
Table 3. Observed (Obs) and expected (Exp) cases of de-novo tumors, Standardized Incidence Ratios (SIR), and 95% Confidence
Intervals (95% CI) among 494 adult recipients who underwent primary liver transplantation, 1983–2009, by years since liver
transplant.
,2 years 2–9 years $10 years
Cancer site/type
(ICD-10 code) Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All cancers but skin
(C00–C43, C44–C97)
11 4.1 2.7 1.3–4.8 19 12.4 1.5 0.9–2.4 11 6.5 1.7 0.8–3.0
Upper aerodigestive
(C00–C14, C30–C33)
0 0.3 – – 4 0.6 6.2 1.7–16.1 0 0.3 – –
Stomach (C16) 1 0.2 6.3 0.2–35.0 0 0.5 – – 0 0.2 – –
Colon (C18) 2 0.3 6.1 0.7–21.9 0 1.0 – – 1 0.6 1.8 0.1–10.1
Lung (C33–C34) 1 0.5 1.9 0.05–10.6 4 1.5 2.6 0.7–6.7 1 0.8 1.2 0.03–7.0
Kaposi’s sarcoma (C46) 5 0.01 393.3 127.7–917.9 2 0.03 65.5 7.9–236.6 0 0.01 – –
Breast (C50) 0 0.5 – – 2 1.6 1.2 0.1–4.5 1 0.9 1.1 0.03–6.3
Vulva (C51.9)* – – – – 1 – – – – – – –
Uterus, cervix (C53) 0 0.03 – – 0 0.1 – – 1 0.05 22.2 0.5–123.8
Prostate (C61) 0 0.4 – – 4 1.3 3.0 0.8–7.8 0 0.8 – –
Bladder (C67) 0 0.3 – – 0 0.9 – – 5 0.5 10.6 3.4–24.7
Central nervous system
(C69–C72)
1 0.1 12.3 0.3–68.4 0 0.2 – – 0 0.1 – –
Hematologic cancers
(C81–C96)
1 0.3 3.0 0.1–16.7 2 0.9 2.1 0.3–7.7 2 0.5 4.3 0.5–15.7
Lymphomas (C81–C85,
C96)
1 0.2 5.2 0.1–28.7 2 0.5 3.7 0.5–13.5 1 0.3 4.0 0.1–22.2
Non-Hodgkin’s
lymphoma (C82–C85,
C96)
1 0.2 6.0 0.2–33.7 1 0.5 2.1 0.05–12.0 1 0.2 4.4 0.1–24.7
Hodgkin’s disease (C81) 0 0.03 – – 1 0.07 14.5 0.3–80.9 0 0.03 – –
Leukemia (C91–C95) 0 0.1 – – 0 0.2 – – 1 0.1 8.3 0.2–46.0
Reference: pool of Italian cancer registries.
doi:10.1371/journal.pone.0065238.t003
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drugs such as Mycofenolate, azathioprine and boluses of
corticosteroids could not be studied.
In general, the published literature [3,9,11,12,32,33,34] agree
that skin cancers, Kaposi’s sarcoma (KP) and post-transplant
lymphoproliferative disorders (PTLD) are the most frequent DNT.
Also, in our study haematological/viral cancers showed the highest
rate (29% of all DNT).
Some authors agree that the highest rate of onset of tumors is in
the first year after transplantation, probably due to a greater initial
immunosuppression. Our study confirms the expected early
appearance of viral/lymphatic tumors. It can be postulated that
early viral/lymphatic tumors may be stimulated by early
immunosuppression whereas other tumors may need a longer
time of stimulation by immunosuppression: so some Authors [10]
report that DNT develop after a time interval ranging from 39 to
77 months post-transplant, that is within 6 years after LT, or,
according to a Finnish study [3], after an average time of is 61
months (5 years). Other Authors [10] found that cancers of the
colon and rectum generally arise later. One advantage of our study
was the long time span. That allowed observation of very late
DNTs. particularly cancers of the bladder in males which had
their onset many years after transplantation. It can be speculated
that the bladder in males is a late target organ of a long lasting
previous immunosuppression.resulting in cancer. It is not clear
why bladder cancer happens mostly in men. The late increase of
bladder tumors has not been previously clearly described in LT
patients and deserve attention. On the basis of this finding, new
follow-up protocols should be developed. However, further
confirmations and explanations are needed.
The study has some limitations. The analysis of the influence of
immunosuppressive drugs had to be limited to calcineurine
inhibitors and to monoclonal antibodies, only. Indeed amount of
steroids, azatiophrine and mycophenolate doses were initially
calculated but that study soon resulted too complicated because of
dose and timing variations occurred through the years, as it often
happens after LT. Such a study can be easily done for short
periods, but not for long-term follow-ups.
The usual blood target levels for calcineurine inhibitors were
applied (Tacrolimus levels targeted between 8–12 ng/ml within
the first 90 days, then lowered; Cyclosporin levels around 200–
300 ng/ml within the first 90 days). The calculation of the entire
load of Cyclosporine or Tacrolimus that each patients received all
along the years was attempted but this analysis is very complex.
We considered OKT3, as that is a very powerful immunosup-
pressive drug that is expected to influence the onset of tumors as it
influences the onset of septic complications. However, in our
analysis no directly correlation was shown between OKT3 and
DNT. This result can be explained by a poor influence of an
‘‘acute’’ immunosuppressive load on the onset of DNT after LT.
As already reported before, an other limitation of this study is
that we were unable to evaluate smoking history in our patients. In
fact, due to study design concerning data even from the ‘80s and
‘90s, some patients’ characteristics of the medical history could not
be retrieved. In Italy the percentage of daily smokers is 24,2% and
higher rates can be found among patients with alcoholic cirrhosis.
As tobacco consumption in our patients is similar to that reported
in other Western countries, and that the medical literature never
mentioned specific observations on bladder tumors to date, we can
argue that smoking history is probably not involved as ethiologic
factor of DNT. Thus our finding of high rates of late onset bladder
cancers remains unexplained.
In recent years, there has been a dramatic decrease in mortality
in transplanted patients with and without DNT, probably due to
an improvement in treatments of liver transplantation and cancer.
However, the onset of a DNT still heavily influences the patient
outcome. The analysis of post LT survival according to different
DNT failed to show any statistical significance among them in this
study (p = 0.71). It is the authors’ opinion that the best approach to
DNT appears to be a very early detection through appropriate
screening protocols. Specifically, whereas detection of Kaposi’s
Figure 1. Kaplan-Meier survivor functions (thick lines) and 95% confidence intervals (95% CI, thin lines) after liver transplantation
or DNT onset.
doi:10.1371/journal.pone.0065238.g001
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sarcoma and lymphomas should be the focus in the early years
after LT, 10 years after LT screening should also focus on the
detection of urological tumors.
Conclusions
This is the largest and longest Italian monocentric study
published so far on DNT occurrence after LT. Males were more
affected. As expected, we observed increased risks of Kaposi’s
sarcoma (in particular in the first 2 years after LT) and of tumors
of the lymphatic system. Interestingly, we observed an increased
incidence of bladder tumors in males.
Multivariate analysis of risk factors identified alcoholic cirrhosis
and sclerosing cholangitis in the recipient as the main risk factors
for the onset of DNT. The use of tacrolimus and cyclosporine as
initial therapy showed no differences with regard to appearance of
DNT.
The risk of mortality at the onset of DNT adjusted for recipient
age and sex, was 4–5 times increased. No differences in survival
was demonstrated among different DNT.
In conclusion, screening protocols for DNT should be
specifically oriented to patients transplanted for alcoholic cirrhosis
and sclerosing cholangitis. The focus should be, as expected, on
Kaposi’s sarcomas early after LT, and, more remarkably, as never
specifically mentioned before, on bladder tumors in men after 10–
15 years from LT.
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